Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus

on behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines. All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different. Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient's clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity. In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs. It will help to choose the appropriate drug for an individual patient with T2DM.

Original languageEnglish
Pages (from-to)357-366
Number of pages10
JournalDiabetes and Metabolism Journal
Volume41
Issue number5
DOIs
Publication statusPublished - 2017 Oct 1

Fingerprint

Hypoglycemic Agents
Type 2 Diabetes Mellitus
Metformin
Practice Guidelines
Hypoglycemia
Meta-Analysis
Body Weight
Guidelines
Therapeutics
Safety
Patient Preference
Comorbidity
Clinical Trials
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Cite this

on behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association (2017). Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. Diabetes and Metabolism Journal, 41(5), 357-366. https://doi.org/10.4093/dmj.2017.41.5.357
on behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association. / Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. In: Diabetes and Metabolism Journal. 2017 ; Vol. 41, No. 5. pp. 357-366.
@article{24f6ebdf3d8a445d9089ddbc87865cd4,
title = "Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus",
abstract = "The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines. All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different. Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient's clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity. In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs. It will help to choose the appropriate drug for an individual patient with T2DM.",
author = "{on behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association} and Moon, {Min Kyong} and Hur, {Kyu Yeon} and Ko, {Seung Hyun} and Park, {Seok O.} and Lee, {Byung Wan} and Kim, {Jin Hwa} and Rhee, {Sang Youl} and Kim, {Hyun Jin} and Choi, {Kyung Mook} and Kim, {Nan Hee} and Kim, {Tae Nyun} and Lee, {Yong Ho} and Kim, {Jin Hwa} and Hong, {Eun Gyoung} and Jaetaek Kim and Lee, {Won Young} and Bokrye Song and Kim, {Ji Young} and Yang, {Dong Hee} and {Taeyoung Yang}, Yang and {Hyeongjin Kim}, Kim",
year = "2017",
month = "10",
day = "1",
doi = "10.4093/dmj.2017.41.5.357",
language = "English",
volume = "41",
pages = "357--366",
journal = "Diabetes and Metabolism Journal",
issn = "2233-6079",
publisher = "Korean Diabetes Association",
number = "5",

}

on behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association 2017, 'Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus', Diabetes and Metabolism Journal, vol. 41, no. 5, pp. 357-366. https://doi.org/10.4093/dmj.2017.41.5.357

Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. / on behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association.

In: Diabetes and Metabolism Journal, Vol. 41, No. 5, 01.10.2017, p. 357-366.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus

AU - on behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association

AU - Moon, Min Kyong

AU - Hur, Kyu Yeon

AU - Ko, Seung Hyun

AU - Park, Seok O.

AU - Lee, Byung Wan

AU - Kim, Jin Hwa

AU - Rhee, Sang Youl

AU - Kim, Hyun Jin

AU - Choi, Kyung Mook

AU - Kim, Nan Hee

AU - Kim, Tae Nyun

AU - Lee, Yong Ho

AU - Kim, Jin Hwa

AU - Hong, Eun Gyoung

AU - Kim, Jaetaek

AU - Lee, Won Young

AU - Song, Bokrye

AU - Kim, Ji Young

AU - Yang, Dong Hee

AU - Taeyoung Yang, Yang

AU - Hyeongjin Kim, Kim

PY - 2017/10/1

Y1 - 2017/10/1

N2 - The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines. All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different. Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient's clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity. In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs. It will help to choose the appropriate drug for an individual patient with T2DM.

AB - The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines. All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different. Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient's clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity. In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs. It will help to choose the appropriate drug for an individual patient with T2DM.

UR - http://www.scopus.com/inward/record.url?scp=85032587605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032587605&partnerID=8YFLogxK

U2 - 10.4093/dmj.2017.41.5.357

DO - 10.4093/dmj.2017.41.5.357

M3 - Review article

AN - SCOPUS:85032587605

VL - 41

SP - 357

EP - 366

JO - Diabetes and Metabolism Journal

JF - Diabetes and Metabolism Journal

SN - 2233-6079

IS - 5

ER -

on behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association. Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. Diabetes and Metabolism Journal. 2017 Oct 1;41(5):357-366. https://doi.org/10.4093/dmj.2017.41.5.357